Endocrine Abstracts

Introduction: Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved for the treatment of relapsing−remitting multiple sclerosis (RRMS). Through an immune reconstitution mechanism, it leads to thyroid autoimmunity in 35% of cases, with Graves’ disease (GD) being the most common presentation. Alemtuzumab-induced GD exhibits distinctive clinical and immunological features, with rarely reported cases of fluctuating thyroid status with documented both blockin...

Objective: To retrospectively evaluate the results of the pheochromocytoma surgery in our institution assessing the surgical complications, perioperative hemodynamic instability and oncologic outcomes.Methods: The medical records of patients admitted for pathologically confirmed pheochromocytoma between 2000 and 2015 were reviewed. Patients with paragangliomas were excluded.Results: We identified 40 patients with 43 resected pheoch...

Introduction: Adrenocortical carcinomas are rare neoplasms with an incidence of 0.7 to 1.5 per million/year. Diagnosis often requires a multidisciplinary approach. When the disease is confined to the adrenal gland, absolute criteria defining malignancy, do not exist, however a score of Weiss> or =a 3 is considered diagnosis. The prognosis is usually reserved and conventional chemotherapy is not curative.Material and Methods: Retrospective analysis of...

Background: Papillary thyroid cancer (PTC) is the most frequent type of well-differentiated thyroid cancer (WDTC) and frequently poses a management dilemma. Its indolent behavior associated with high long term survival support the trend towards a more conservative management approach. The authors present a case of isolated bone metastases as the form of presentation of papillary thyroid carcinoma. A 61-year-old man was admitted with complaints of lower back pain for the previo...